GlassScriptPhysician profile
Vishal Agrawal
NPI 1902995178
$1,898.40
in general payments reported to CMS, 2019-2025
27 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $281 · 2021: $127 · 2022: $109 · 2023: $130 · 2024: $171 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $264.12 | 2019-2021 | |
| Insmed, INC. | $257.39 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $241.37 | 2019-2024 | Nucala |
| Mylan Specialty L.P. | $193.71 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.34 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $92.41 | 2019-2024 | Airsupra |
| Grifols USA, LLC | $91.59 | 2019-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $71.38 | 2024-2025 | |
| Circassia INC. | $62.23 | 2019 | |
| Advanced Respiratory, INC | $56.40 | 2019-2020 | |
| Genentech USA, INC. | $43.33 | 2019-2024 | Xolair |
| Amgen INC. | $41.32 | 2024-2025 | Tezspire |
| Inspire Medical Systems, INC. | $34.07 | 2023 | Inspire |
| Actelion Pharmaceuticals US, INC. | $33.42 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $26.13 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $25.76 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $25.30 | 2020-2021 | |
| Abbvie INC. | $24.91 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $23.06 | 2025 | Lumryz |
| Shire North American Group INC | $22.00 | 2019 | |
| United Therapeutics Corporation | $21.51 | 2022 | |
| Olympus America INC. | $20.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.98 | 2023 | |
| Electromed, INC. | $14.98 | 2024 | Smartvest |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.92 | 2022 | |
| Itamar Medical INC | $12.13 | 2025 | Watchpatone |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.